Detecting Tumor Specific Amplitude-modulated Frequencies of Cancer Patients

Neoplasms Clinical Trial

Official title:

Detecting Tumor Specific Amplitude-modulated Frequencies of Cancer Patients In Vivo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03037840
• Other study ID #: SXXin-AM-RF-EMF-in vivo
• Status: Not yet recruiting
• Start date: December 2018
• Est. completion date: June 2020

Study information

• Verified date: October 2018
• Source: Southern Medical University, China
• Contact: Xin Sherman Xuegang, professor
• Phone: 008613602733465
• Email: xxg[@]smu.edu.cn
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Studies have shown that tumor specific amplitude-modulated frequencies of radiofrequency electromagnetic fields that is associated with biofeedback upon exposure to in cancer patients. However, such discovery in other cancer patients are rare. And whether tumor specific frequencies can be found in Asian cancer patients remains unclear. The purpose of this study is to detect the tumor specific frequencies of Asian cancer patients in vivo.

Description:

The measurements were safety guaranteed and were conducted in hospital. Before detecting, the patient will be already diagnosed with cancer. The doctor and the operator are responsible for the detecting. When cancer patients are exposure to the RF electromagnetic fields, the radial pulse amplitude, blood pressure, skin electrical resistance and breath will be monitored. Biofeedback parameters will be recorded at different modulation frequencies and analyzed in order to find the variation and tumor specific frequencies.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 200
• Est. completion date: June 2020
• Est. primary completion date: June 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Clinical diagnosis of cancer Disease

Exclusion Criteria:

• other patients

Related Conditions & MeSH terms

• Neoplasms

Intervention

Device:
• Low intensity amplitude-modulated RF EMFs
Low intensity amplitude-modulated radiofrequency electromagnetic fields,the carrier frequency is 27.12MHz with a power of about 100mW

Locations

Country	Name	City	State
n/a

Sponsors (4)

Lead Sponsor	Collaborator
Southern Medical University, China	Guangdong 999 Brain Hospital, Nanfang Hospital of Southern Medical University, The 157th Hospital of PLA,China

References & Publications (4)

Barbault A, Costa FP, Bottger B, Munden RF, Bomholt F, Kuster N, Pasche B. Amplitude-modulated electromagnetic fields for the treatment of cancer: discovery of tumor-specific frequencies and assessment of a novel therapeutic approach. J Exp Clin Cancer Res. 2009 Apr 14;28:51. doi: 10.1186/1756-9966-28-51. — View Citation

Costa FP, de Oliveira AC, Meirelles R, Machado MC, Zanesco T, Surjan R, Chammas MC, de Souza Rocha M, Morgan D, Cantor A, Zimmerman J, Brezovich I, Kuster N, Barbault A, Pasche B. Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields. Br J Cancer. 2011 Aug 23;105(5):640-8. doi: 10.1038/bjc.2011.292. Epub 2011 Aug 9. — View Citation

Zimmerman JW, Jimenez H, Pennison MJ, Brezovich I, Morgan D, Mudry A, Costa FP, Barbault A, Pasche B. Targeted treatment of cancer with radiofrequency electromagnetic fields amplitude-modulated at tumor-specific frequencies. Chin J Cancer. 2013 Nov;32(11):573-81. doi: 10.5732/cjc.013.10177. Review. — View Citation

Zimmerman JW, Pennison MJ, Brezovich I, Yi N, Yang CT, Ramaker R, Absher D, Myers RM, Kuster N, Costa FP, Barbault A, Pasche B. Cancer cell proliferation is inhibited by specific modulation frequencies. Br J Cancer. 2012 Jan 17;106(2):307-13. doi: 10.1038/bjc.2011.523. Epub 2011 Dec 1. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Biofeedback response of cancer patients at the exposure of Low intensity amplitude-modulated radiofrequency electromagnetic fields		within 20 min of exposure
Secondary	Representation of autonomous response during the exposure of tumor specific frequencies modutated RF eletromagnetic fields		within 20 min of exposure